Operator Note No. XLIII

Start here. The three-compound foundation.

Every optimization protocol begins with the same clinical question: given this patient's labs, goals, and baseline, which three compounds produce the most signal with the least confound? The starter stack is not a default. It is a precision selection from a decision framework.

Operator Note XLIII Protocol Sequencing May 2026

I. Why three compounds to start.

Starting with more than three compounds simultaneously creates an attribution problem. If the patient improves, the clinician cannot determine which compound drove the result. If the patient has an adverse effect, the clinician cannot determine the source. The information value of the experiment collapses before it begins.

The rule: introduce one or two compounds at a time, observe for 6 to 8 weeks, then add the next tier. This is not caution for its own sake. It is the only way to build a protocol that is clinically legible.

A patient who starts testosterone, a GH secretagogue, BPC-157, thymosin alpha-1, NAD+, and vitamin D simultaneously has given their clinician an uninterpretable data set. When they feel better at week 8, nothing has been learned. When they have a problem at week 12, nothing can be diagnosed. Sequenced introduction is a clinical epistemology requirement, not a conservative preference.

II. The universal foundation layer (before any peptide or hormone).

These interventions precede any compound introduction. They are not preliminary. They are the protocol. The compounds are added to an optimized foundation. Without this layer, every subsequent compound operates at reduced efficiency.

Micronutrient correction

Vitamin D to 60 to 70 ng/mL. Magnesium glycinate 400 mg/day. Zinc picolinate 25 mg/day. Allow 8 to 12 weeks to normalize. Start immediately at intake.

Omega-3 substrate

2 to 4 g EPA+DHA daily. Anti-inflammatory substrate correction. This is foundational, not supplemental.

Sleep architecture

If obstructive sleep apnea is present, treat it first. If sleep is fragmented for other reasons, address the cause before starting GH secretagogues. Secretagogues require slow-wave sleep to produce their effect. Prescribing them before sleep is repaired is prescribing into a broken receptor environment.

Protein floor

1.6 g/kg/day minimum, established and verified. If the patient cannot sustain this, start with dietary coaching before compounds. Anabolic signaling without anabolic substrate produces no outcome.

Resistance training

3 sessions per week minimum with progressive overload. If not present, this is the first intervention. A compound protocol without training stimulus is optimizing a system that has no reason to adapt.

The universal foundation layer is not optional and is not a preliminary. It is the protocol. The compounds are added to an optimized foundation. Without this layer, every subsequent compound operates at reduced efficiency. This is not conventional medicine being cautious. It is optimization medicine being rigorous.

III. Tier 1 starter stacks by patient profile.

Profile A: Metabolic focus (insulin resistance, body composition, GLP-1 user)

Compound 1: Semaglutide or tirzepatide (if indicated), or MOTS-c (if pharmaceutical GLP-1 is not indicated). Addresses the metabolic axis directly.

Compound 2: BPC-157. Gut barrier protection (particularly relevant with GLP-1 use) and anti-inflammatory signaling.

Compound 3: NAD+ precursor (NMN 500 mg/day). Metabolic resilience support at the mitochondrial level.

Profile B: Hormonal optimization (TRT candidate, age-related decline)

Compound 1: Testosterone (if labs confirm hypogonadism or low-normal with symptoms). Foundation hormone. Nothing else in the hormonal optimization tier is meaningful before this is established.

Compound 2: CJC-1295 plus ipamorelin at bedtime. Addresses somatropause concurrent with the testosterone axis.

Compound 3: Vitamin D (already in foundation; elevate to 5,000 IU/day during the hormonal introduction phase for VDR support and cofactor coverage).

Profile C: Performance and recovery (athlete or high-training-volume patient)

Compound 1: BPC-157. Primary tissue repair and gut mucosal support.

Compound 2: TB-500 (thymosin beta-4). Actin sequestration and systemic tissue repair: a complement to BPC-157, not a substitute for it.

Compound 3: CJC-1295 plus ipamorelin. GH pulse amplification for recovery depth and body composition trajectory.

Profile D: Longevity and cognitive focus (biologically older patient, cognitive decline concern)

Compound 1: NMN 500 mg/day plus SS-31. Mitochondrial tier, dual coverage: substrate and membrane protection.

Compound 2: Semax. BDNF upregulation and cognitive enhancement with a well-characterized safety profile.

Compound 3: GHK-Cu. Gene expression modulation, anti-inflammatory signaling, and collagen architecture support.

IV. The 6-to-8-week assessment.

At 6 to 8 weeks after Tier 1 introduction: lab recheck (the markers specific to the compounds introduced), subjective outcome assessment across all seven domains, and body composition measurement.

Three questions to answer at this interval: Is the primary presenting complaint improving? Are labs moving in the expected direction? Can any adverse effects be attributed to a specific compound?

If clear response is present: add Tier 2. If response is unclear: hold at Tier 1 for another 4 to 6 weeks, or adjust the Tier 1 compound, before adding anything new. The decision gate is the data, not the calendar.

The Accumulation Problem

The clinician who adds a new compound at every visit without assessing response to the prior compound is not practicing optimization medicine. They are practicing compound accumulation. The patient's stack grows. The clinical legibility decreases. The outcome attribution becomes permanently impossible. Resist the urgency to add. The protocol that works is the one the clinician understands, not the longest one.

V. Tier 2 additions (weeks 8 to 24).

After Tier 1 is stable and response is confirmed, the following additions are available by indication:

Thymosin alpha-1 if the immune tier is indicated: recurrent infections, inflammatory burden, or autoimmune history in the chart.

Epithalon (annual or semi-annual course) if longevity axis is the patient's stated priority and biological age data supports the intervention.

PT-141 if libido or sexual function is a persistent complaint not resolved by hormonal optimization at Tier 1.

DHEA if adrenopause is confirmed: DHEA-S below 150 mcg/dL in men, with corroborating symptoms.

Magnesium malate for daytime energy (distinct from magnesium glycinate for sleep; the two serve different functions and are not interchangeable).

VI. Tier 3 (advanced, months 6 and beyond).

Mitochondrial tier: MOTS-c and SS-31 if not already present in Tier 1. For the patient with documented metabolic or functional decline and biological age data supporting the investment.

Cognitive tier: Dihexa if Semax response has plateaued and cognitive optimization remains the primary objective.

Longevity deep tier: Cerebrolysin (IV course, annually). Dasatinib plus quercetin senolytic pulse (quarterly). Both require the patient to have strong biological age data motivating further intervention and the clinical sophistication to understand the evidence tier of what they are undertaking.

Most patients never need Tier 3. Tier 1 and Tier 2, built on a solid foundation, produce most of the clinical benefit available from optimization medicine. Tier 3 is for the patient who has maximized Tier 1 and Tier 2, has strong biological age data motivating further intervention, and has the clinical sophistication to understand the evidence tier of what they are doing. The goal of the starter stack is not to reach Tier 3. The goal is to find what works, understand why, and build from there.

References

Bhasin S et al. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. Tier 1 Profile B anchor: testosterone indication thresholds and monitoring protocol. verified
Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. STEP 1 trial. Tier 1 Profile A anchor: GLP-1 receptor agonist metabolic outcomes. verified
Schoenfeld BJ. The Mechanisms of Muscle Hypertrophy and Their Application to Resistance Training. J Strength Cond Res. 2010;24(10):2857-2872. Foundation layer anchor: resistance training as required substrate for anabolic protocols. verified
Holick MF. Vitamin D Deficiency. N Engl J Med. 2007;357(3):266-281. Foundation layer anchor: vitamin D repletion targets and deficiency prevalence. verified
Morton RW et al. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults. Br J Sports Med. 2018;52(6):376-384. Foundation layer anchor: protein floor requirement for anabolic adaptation. verified

THE PIVOTAL PROTOCOL is an intelligence and education layer, not a prescriber. The sequencing frameworks described here are derived from clinical literature and from THE PIVOTAL PROTOCOL's own protocol design history. Every clinical decision belongs to a licensed physician with full knowledge of the case. Begin a conversation. Do not begin self-administration from a website.